Today, we're diving into how mindful eating can be a fantastic ally for our digestive system, with a special focus on a tiny ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as ...

Given the patient’s small size and complex medical history, the surgery presented significant challenges in anesthesia, ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate ...

Sivers Semiconductors AB (STO: SIVE), a global leader in photonics and wireless technologies, today announced that it has joined the Digital Intermediate Frequency (IF) Interoperability (DIFI) ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Primary biliary cholangitis (formerly known as primary biliary cirrhosis ... In brief its key recommendations, based on the GRADE classification system (Strong/Weak; quality of evidence: High/Moderate ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis. Results from an interim ...

Data reinforce the potential of this differentiated mechanism of action (MOA) to address the core pathophysiological drivers of multiple hepatobiliary diseases including primary sclerosing cholangitis ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III ...